Abstract
Several years after the introduction of cholinergic drugs in Alzheimer’s disease therapy, other approaches for symptomatic and also disease-modifying pharmacotherapy are progressing in their development. Among these, the NMD A antagonist memantine represents the most advanced and promising agent, gifted with many years of clinical experience in Germany. This paper provides an overview of both, the novel pharmacological background and recent clinical evidence in dementia. Memantine was recently recommended for central European approval.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8: 565–571
Cacabelos R, Takeda M, Winblad B (1999) The glutamatergic system and neurode-generation in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry 14(1): 3–47
Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G (2000) Neuroprotection and symptomatological action of memantine relevant for Alzheimer’s disease ¡ª an unified hypothesis on the mechanism of action. Neurotox Res 2(2–3): 85–98
Davies P (1999) Challenging the cholinergic hypothesis in Alzheimer disease [editorial]. JAMA 281(15): 1433–1444
Ditzler K (1991) Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 41: 773–780
Fratiglioni L, De Ronchi D, Agtiero-Torres H (1999) Worldwide prevalence and incidence of dementia. Drugs Ageing 15:365–375
Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimers Dis Assoc Disord ll[Suppl 2]: 33–39
Galasko DR, Schmitt FA, Jin S, Saxton J, Bennett D, Sano M, Ferris SH (2000) Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer’s disease. Neurobiol Aging 21(1S): 168
Gortelmeyer R, Erbler H (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelfor-schung/Drug Res 42(7): 904–913
Greenamyre J, Young A (1989) Excitatory amino acids and Alzheimer’s disease. Neurobiol Aging 10: 593–602
Jorm AF, Jolley D (1998) The incidence of dementia: a meta-analysis. Neurology 51(3):728–733
Kornhuber J, Weller M (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41(2): 135–144
Lancelot E, Beal MF (1998) Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 116: 331–347
Launer LJ, Hofman A (2000) Frequency and impact of neurologic diseases in the elderly of Europe: a collaborative study of population-based cohorts. Neurology 54[11 Suppl5]: 1–8
Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR,Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54[11 Suppl5]: S4–9
Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke (in press)
Palmer AM, Gershon S (1990) Is the neuronal basis of Alzheimer’s disease cholinergic or glutamergic? FASEB J 4: 2745–2752
Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993) Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (l-amino-3,5-dimethyladamantan). Neuropharmacology 32(12): 1337–1350
Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11(9): 523–569
Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stoffler A, Mobius HJ (2000) Memantine in moderately severe to severe Alzheimer’s disease (AD): results of a placebo-controlled 6-month trial. Neurobiol Aging 21(1S): S275
Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7(5): 486–488
Sahin K, Stoffler A, Furtuna P, Rosenwald D, Mobius HJ (2000) Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Neurobiol Aging 21 (IS):S168
Saxton J, McGonigle KL, Swihart AA, Boiler F (1993) The Severe Impairment Battery. The University of Pittsburgh of the Commonwealth System of Higher Education (eds) Thames Valley Test Company, Suffolk, pp 1–16
Sclan SG, Reisberg B (1992) Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Int Psychoger 4[Suppl 1]: 55–69
Szatkowski M, Atwell D (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 17(9): 359–365
van der Kam P, Mol F, Wimmers MFHC (1986) [Assessment scale for geriatric patients] Beordelingsschaal voor Oudere Patienten (BOP). Van Loghum Slaterus, The Netherlands
Wilcock G, Mobius HJ, Stoffler A, on behalf of the MMM 5000 Group (2002) A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol (in press)
Winblad B, Poritis N (1999) Memantine in severe dementia, results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psych 14(2): 135–146
Winblad B, Wimo A, Mobius HJ, Fox JM, Fratiglioni L (1999) Severe dementia: a common condition entailing high costs at individual and societal levels. Int J Geriatr Psychiatry 14(11): 911–914
Zajaczkowski W, Quack G, Danysz W (1996) Infusion of (+)-MK-801 and memantine ¡ªContrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296: 239–246
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Wien
About this paper
Cite this paper
Winblad, B., Möbius, H.J., Stöffler, A. (2002). Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?. In: Jellinger, K.A., Schmidt, R., Windisch, M. (eds) Ageing and Dementia Current and Future Concepts. Journal of Neural Transmission. Supplementa, vol 62. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6139-5_20
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6139-5_20
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83796-2
Online ISBN: 978-3-7091-6139-5
eBook Packages: Springer Book Archive